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Abstract
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non–
small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. We hypothesized that both signal
transducer and activator of transcription 3 (STAT3) and Src-YES-associated protein 1 (YAP1) signaling are dually activated
during EGFR TKI treatment to limit therapeutic response.
Methods: We used MTT and clonogenic assays, immunoblotting, and quantitative polymerase chain reaction to evaluate the
efficacy of EGFR TKI alone and in combination with STAT3 and Src inhibition in three EGFR-mutant NSCLC cell lines. The
Chou-Talalay method was used for the quantitative determination of drug interaction. We examined tumor growth inhibi-
tion in one EGFR-mutant NSCLC xenograft model (n¼4 mice per group). STAT3 and YAP1 expression was evaluated in tumors
from 119 EGFR-mutant NSCLC patients (64 in an initial cohort and 55 in a validation cohort) by quantitative polymerase chain
reaction. Kaplan-Meier and Cox regression analyses were used to assess the correlation between survival and gene expres-
sion. All statistical tests were two-sided.
Results: We discovered that lung cancer cells survive initial EGFR inhibitor treatment through activation of not only STAT3
but also Src-YAP1 signaling. Cotargeting EGFR, STAT3, and Src was synergistic in two EGFR-mutant NSCLC cell lines with a
combination index of 0.59 (95% confidence interval [CI] ¼ 0.54 to 0.63) for the PC-9 and 0.59 (95% CI¼0.54 to 0.63) for the H1975
cell line. High expression of STAT3 or YAP1 predicted worse progression-free survival (hazard ratio [HR] ¼ 3.02, 95% CI¼1.54
to 5.93, P ¼ .001, and HR¼2.57, 95% CI¼1.30 to 5.09, P ¼ .007, respectively) in an initial cohort of 64 EGFR-mutant NSCLC
patients treated with firstline EGFR TKIs. Similar results were observed in a validation cohort.
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Conclusions: Our study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits
targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize re-
sidual disease and enhance clinical outcomes.
Activating epidermal growth factor receptor (EGFR) kinase
domain mutations are present in a meaningful number of
non–small cell lung cancer (NSCLC) patients (1). Although the
EGFR tyrosine kinase inhibitors (TKIs) collapse an extensive
downstream signaling network in EGFR-mutant NSCLC that
often elicits an initial antitumor response in patients (2,3),
only approximately 5% of patients achieve more than 90%
tumor reduction solely with an EGFR TKI (eg, erlotinib) and
virtually all patients relapse on treatment, with a median
progression-free survival of less than one year (4). Mutant
EGFR inhibition in cell cultures mimics this clinical experi-
ence, with approximately 5% of cells remaining viable one
week after EGFR inhibition as drug-tolerant or -resistant re-
sidual disease cells. These residual surviving cells then grow
to form drug-resistant colonies that manifest as tumor
relapse (acquired resistance) (3).
EGFR mutations activate phosphatidylinositol 3-kinase
(PI3K)/AKT, Janus kinase 2 (JAK2)/signal transducer and activa-
tor of transcription 3 (STAT3), but less so Ras/mitogen-
activated protein kinase (MAPK) (5,6). EGFR inhibition produces
an imbalance in EGFR signaling, promoting some signaling
pathways while impairing others (6). STAT3 is activated almost
immediately after erlotinib or gefitinib treatment (7,8) by tyro-
sine phosphorylation in part, downstream of interleukin-6
(IL-6) (9). We previously showed that EGFR inhibition induces
an EGFR-TNF receptor–associated factor 2 (TRAF2) receptor in-
teracting protein 1 (RIP1) inhibitor of nuclear factor kappa-B
kinase (IKK) complex (EGFR-TRAF2-RIP1-IKK) and stimulates a
nuclear factor-kappa B (NF-jB)–mediated transcriptional pro-
gram that includes IL-6-STAT3 signaling upregulation (10). We
also found that increased expression of the NF-jB inhibitor IjB
was associated with better outcome in erlotinib-treated
EGFR-mutant NSCLC patients (11). In addition to STAT3, IL-6
activates the Src family kinases (SFK; such as YES) and subse-
quently YES-associated protein 1 (YAP1) (12). Therefore, con-
trol of EGFR pathway activity occurs at multiple levels within
the signal cascade and involves crosstalk and signal integra-
tion with other pathways such as IL-6 signaling, modifying the
cellular response to EGFR TKI treatment (13).This connection
between IL-6 activation and multiple downstream survival
pathways including STAT3 and Src-YAP1 prompted us to ex-
plore the role of dual activation of STAT3 and Src-YAP1 in
modulating the initial EGFR TKI response in lung cancer. While
YAP1 activation can limit the response to RAF- and MEK-
targeted therapies in BRAF- and RAS-mutant cancers (14), the
role of YAP1 in limiting EGFR TKI response, particularly in con-
cert with other key survival factors such as STAT3, has not
been established.
In the current study, we hypothesized that Src-YAP1 signal-
ing functions in conjunction with parallel STAT3 activation, po-
tentially downstream of IL-6, to limit initial EGFR TKI response.
We aimed to evaluate whether cotargeting EGFR, STAT3, and
Src-YAP1 can improve responses in EGFR-mutant NSCLC mod-
els in comparison with single EGFR inhibition. Finally, in two in-
dependent cohorts of EGFR-mutant NSCLC patients treated
with firstline EGFR TKIs, we explored STAT3 and YAP1 messen-
ger RNA (mRNA) expression as predictors of progression-free
survival.
Methods
Sample Collection
Pretreatment tumor specimens from advanced EGFR-mutant
NSCLC patients were retrospectively collected from eight sites
in Spain, France, Italy, and Colombia (Table 1). For the validation
cohort, pretreatment tumor samples from advanced EGFR-
mutant NSCLC patients were retrospectively collected from
the Department of Oncology of Shanghai Pulmonary Hospital,
affiliated with Shanghai Tongji University School of Medicine
(Table 1). Clinical data were assessed in accordance with the
protocol approved by the institutional review board of Germans
Trias i Pujol Hospital, Badalona, Spain, and de-identified for pa-
tient confidentiality.
Chemicals and Reagents
The first-generation EGFR TKI gefitinib was purchased from
Tocris Bioscience. TPCA-1 (2-[(aminocarbonyl)amino]-5-
(4-fluorophenyl)-3-thiophenecarboxamide), a nonpeptidic small
molecule inhibitor of the inhibitor of jB kinase-2 (IKK2) (15), and
the Src homology 2-domain of STAT3 (16), was purchased from
Sigma Aldrich. AZD0530 (SFK inhibitor; saracatinib) and the
third-generation EGFR TKI AZD9291 were purchased from
Selleck Chemicals. Drugs were prepared in dimethyl sulfoxide
(DMSO) at a concentration of 10 to 100 mmol/L stock solution
and stored at 20C. Further dilutions were made in culture me-
dium to final concentration before use. Other chemicals and re-
agents used are described in the Supplementary Methods
(available online).
Cell Lines
Human lung adenocarcinoma PC-9 cells harboring EGFR exon 19
deletion (E746-A750) were provided by F. Hoffmann-La Roche,
Ltd, Basel, Switzerland, with the authorization of Dr. Mayumi
Ono (Kyushu University, Fukuoka, Japan). Human lung adeno-
carcinoma 11-18 cells harboring EGFR exon 21 L858R mutation
were provided by Dr. Mayumi Ono, respectively. Human lung
adenocarcinoma H1975 cells harboring both sensitizing L858R
and resistant T790M mutations were purchased from the
American Type Culture Collection (ATCC); Manassas, VA, USA.
All cell lines were maintained in RPMI (Roswell Park Memorial
Institute medium) 1640 supplemented with 1% penicillin/strep-
tomycin/glutamine (Gibco) and 10% fetal bovine serum (FBS;
Gibco) in a 5% CO2 37C cell culture incubator and routinely
evaluated for mycoplasma contamination.
Cell Viability Assay
Cells were seeded on 96-well plates and treated with serial dilu-
tions of the drugs administrated at doses typically correspond-
ing to 1/8, 1/4, 1/2, 5/8, 3/4, 7/8, 1, 1.5, and 2 of the individual half
maximal inhibitory concentration (IC50) values. Cell viability was
then assessed with MTT (tetrazolium-based semiautomated
colorimetric 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
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bromide) reagent. Data of combined drug effects were ana-
lyzed using the Chou and Talalay method (17) and are the av-
erage of three independent experiments. Combination index
values of less than 1, 1, and more than 1 indicated synergism,
additive effect, and antagonism, respectively. The mean val-
ues of the survival fractions were used to generate a set of CI
values (data points) and construct the growth inhibition
curves and the isobologram for a particular cell line and drug
combination. The mean combination index value (mCI) for
this set was reported as the summary measure of three inde-
pendent experiments for each cell line. The associated 95%
confidence intervals (CIs) are also reported. Further details
are provided in the Supplementary Methods (available
online).
Colony Formation Assay
To test the inhibitory effect of EGFR TKIs alone or in combina-
tion with other compounds, the cytotoxicity assay based on col-
ony formation was performed, as described in the
Supplementary Methods (available online).
Immunoblotting
Whole cell lysates were prepared, and equivalent amounts of
protein were detected with appropriate primary antibodies.
Details are provided in the Supplementary Methods (available
online).
Animal Experiments
All mouse procedures were based on National Institutes of
Health (NIH) Guide for Care and Use of Laboratory Animals and
approved by Institutional Animal Care and Use Committee of
Jiangsu Province Academy of Traditional Chinese Medicine
(SYXK-2011-0017). Four- to five-week-old female nude mice
were obtained from Nanjing Biomedical Research Institute of
Nanjing University and maintained in a clean facility in the
Jiangsu Province Academy of Traditional Chinese Medicine
(Nanjing, Jiangsu, China). Details are provided in the
Supplementary Methods (available online).
Real-time PCR Analysis
RNA was isolated from the tumor tissue specimens and cell
lines as previously described (18). mRNA gene expression analy-
sis was performed by TaqMan-based quantitative reverse tran-
scription polymerase chain reaction (qRT-PCR) as described in
the Supplementary Methods (available online).
The primer and probe sets for the genes analyzed were de-
signed using Primer Express 3.0 Software (Applied Biosystems)
according to their Ref Seq (http://www.ncbi.nlm.nih.gov/
locuslink) (Supplementary Table 1, available online).
Statistical Analysis
Progression-free and overall survival were estimated by the
Kaplan-Meier method and compared using a nonparametric
log-rank test. Gene expression levels were divided into two
groups according to median relative expression. A Cox propor-
tional regression model was applied to calculate hazard ratios
(HRs) and their 95% confidence intervals. Statistical analyses
were performed using SAS version 9.3. Details are provided in
the Supplementary Methods (available online). All statistical
tests were two-sided, and a P value of less than .05 was consid-
ered statistically significant.
Results
Impact of STAT3 and Src-YAP1 Inhibition on the Effect
of Gefitinib on EGFR Downstream Signaling Pathways
We first evaluated the effect of gefitinib and AZD9291 (a recent
US Food and Drug Administration [FDA]–approved third-
generation EGFR TKI, also called osimertinib, with activity
against EGFR T790M), with or without TPCA-1 (a STAT3 inhibi-
tor), on EGFR downstream signal transduction pathways.
Table 1. Patient characteristics of the 64 patients of the initial cohort
and the 55 patients of the validation cohort included in the present
study
Clinical
characteristics
Initial
cohort, No. (%)
Validation
cohort, No. (%)
Sex
Male 22 (34.4) 36 (65.4)
Female 42 (65.6) 19 (34.6)
Age, y
Median 67 58
Range 35 89 50  69
ECOG performance status
0 15 (23.4) 2 (3.7)
1 49 (76.6) 51 (92.7)
>1  2 (3.6)
Smoking status
Never smoked 42 (65.6) 49 (89.1)
Former smoker 17 (26.6) 4 (7.3)
Current smoker 5 (7.8) 2 (3.6)
Disease stage
IIIB 12 (18.7) 7 (12.7)
IV 52 (81.3) 48 (87.3)
Brain metastasis
No 43 (67.2) 37 (67.3)
Yes 21 (32.8) 18 (32.7)
Bone metastasis
No 40 (62.5) 22 (40.0)
Yes 24 (37.5) 33 (60.0)
Type of EGFR mutation
Exon 19 deletion 44 (68.8) 36 (65.5)
L858R 18 (28.1) 19 (34.5)
Other* 2 (3.1)
Type of EGFR TKI
Erlotinib 37 (57.8) 7 (12.7)
Gefitinib 25 (39.1) 45 (81.8)
Afatinib/icotinib 2 (3.1); afatinib 3 (5.5); icotinib
Progression-free survival
Median (95% CI), mo 14.1 (8.8 to 16.3) 9.8 (7.1 to 11.1)
Overall survival
Median (95% CI), mo 26.7 (17.9 to 37.1) Not reached
Best response
Complete response 3 (4.7) 
Partial response 39 (60.1) 31 (56.4)
Stable disease 16 (25.8) 14 (25.5)
Progressive disease 6 (9.4) 7 (12.7)
Not evaluable  3 (5.4)
*Other, L861Q, G719X. CI ¼ confidence interval; ECOG ¼ Eastern Cooperative
Oncology Group; TKI ¼ tyrosine kinase inhibitor.
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Gefitinib suppressed EGFR, ERK1/2, and AKT phosphorylation
but increased STAT3 phosphorylation on the critical tyrosine
residue 705 (pSTAT3-Tyr705) in a time- and dose-dependent
manner in PC-9 cells that harbor EGFR exon19 deletion (E746-
A750) (Figure 1A). Gefitinib plus TPCA-1 abolished pSTAT3-
Tyr705 phosphorylation (Figure 1B). PC-9 cells showed increased
STAT3 and Rantes (regulated upon activation, normal T-cell ex-
pressed, and presumably secreted) mRNA levels following gefi-
tinib treatment, an effect not observed when gefitinib was
combined with TPCA-1 (Figure 1C). Rantes expression is depen-
dent on a transcription complex of STAT3 with NF-jB (19).
pSTAT3-Tyr705 was also induced by gefitinib alone in 11-18
cells that harbor EGFR exon 21 L858R mutation and was dimin-
ished with gefitinib plus TPCA-1 (Figure 1D). We then evaluated
the effect of AZD9291 with or without TPCA-1 in the H1975 cell
line, which harbors EGFR T790M that is resistant to first-
generation EGFR TKIs (erlotinib, gefitinib). AZD9291 suppressed
EGFR, ERK1/2, and AKT phosphorylation but not pSTAT3-
Tyr705, while AZD9291 plus TPCA-1 abolished pSTAT3-Tyr705
(Figure 1E).
Given that IL-6 can activate STAT3 as well as other pathways
such as YAP1, we hypothesized that YAP1 signaling might limit
EGFR TKI response in EGFR-mutant cells. Interestingly, IL-6 can
act via the kinase Src to promote YAP1 signaling in other epithe-
lial contexts, but the role of this potential Src-YAP1 signaling
has not been explored in lung cancer to our knowledge (12).
Consistent with our hypothesis, we found that EGFR TKI treat-
ment led to increased expression of the YAP1 target connective
tissue growth factor (CTGF) in the treated EGFR-mutant cell
population over time (Figure 2). Interestingly, we found that
combined treatment with the STAT3 inhibitor TPCA-1 and gefi-
tinib did not ablate this increase in CTGF expression (Figure 2).
This observation suggested that YAP1 is engaged via another
mechanism beyond solely EGFR or STAT3 signaling.
We therefore considered the alternative possibility that Src
may be critical for YAP1 activation in EGFR-mutant cells as Src
can phosphorylate paxillin and promote YAP1 activation in cer-
tain other epithelial cells (12). We tested the effect of the SFK in-
hibitor AZD0530 in this system. Gefitinib alone was unable to
suppress the phosphorylation of STAT3, paxillin, or YAP1 in PC-
9 cells (Figure 3A). Gefitinib plus AZD0530 blocked paxillin and
YAP1 phosphorylation on tyrosines 118 and 357 but had no ef-
fect on pSTAT3-Tyr705 in PC-9 cells (Figure 3A). Gefitinib plus
TPCA-1 blocked STAT3 but had no effect on paxillin and YAP1
phosphorylation. The triple combination of gefitinib, TPCA-1,
and AZD0530 inhibited STAT3, paxillin, and YAP1 phosphoryla-
tion. Phosphorylation of YAP1 on serine 127, which causes cyto-
plasmic retention of YAP1, was not affected by any treatment
(Figure 3A). Similar results were observed with the triple combi-
nation of AZD9291, TPCA-1, and AZD0530 in H1975 cells (Figure
3B). Thus, activation of Src, acting upstream of YAP1, is a previ-
ously unrecognized event in the initial biochemical adaptation
to EGFR TKI treatment in EGFR-mutant NSCLC cells. These re-
sults show that the efficacy of EGFR TKIs in EGFR-mutant
NSCLC cell lines might be attenuated by STAT3 and Src-YAP1
pathway co-activation and that this process can be reversed by
additional STAT3 and Src inhibition.
In Vitro Effect of Gefitinib in CombinationWith STAT3
and Src Inhibitors
Based on our findings linking dual STAT3 and Src-YAP1 signal-
ing to the adaptive signaling response that is induced by EGFR
TKI treatment in EGFR-mutant lung cancer cells, we then as-
sessed the growth inhibitory effects of combinations of EGFR
with STAT3 and Src inhibition. As shown in Figure 3C, a 72-hour
exposure to gefitinib and TPCA-1 resulted in a synergism in PC-
9 cells with an mCI of 0.82 (95% CI ¼ 0.80 to 0.84). A synergism
was also observed by adding AZD0530 to gefitinib in PC-9 cells
with an mCI of 0.80 (95% CI ¼ 0.78 to 0.82) (Figure 3C). The triple
combination of gefitinib, TPCA-1, and AZD0530 was highly syn-
ergistic, with an mCI of 0.59 (95% CI ¼ 0.54 to 0.63) (Figure 3C). In
addition, the triple combination of AZD9291, TPCA-1, and
AZD0530 was synergistic in H1975 cells, as shown by the isobo-
logram analysis and the representative curves in Figure 3D,
where experimental data points are below the calculated addi-
tivity line, indicating synergistic effects of the combination. PC-
9 cells treated with the double combinations failed to form as
many colonies as cells treated with gefitinib alone, and the few
cells surviving the triple combination generated even fewer col-
onies than cells surviving the double combinations (Figure 3E);
overall, the results from the clonogenic assay were consistent
with the MTT data.
Gefitinib in CombinationWith STAT3 and Src Inhibitors
In Vivo
Given the role of co-activation of STAT3 and Src-YAP signaling
in limiting the magnitude of initial EGFR TKI response and the
inhibitory effect of the triple combination of EGFR TKIs with
TPCA-1 and AZD0530, we explored whether this in vitro effect
was translated into in vivo model systems. PC-9 cells were in-
jected into mice and treated with gefitinib, TPCA-1, and
AZD0530 alone, or double and triple combinations. Stronger tu-
mor regression was observed with gefitinib plus TPCA-1 (P <
.001) or AZD0530 (P < .001), compared with gefitinib alone. The
triple combination of gefitinib, TPCA-1, and AZD0530 had
greater effect than gefitinib plus TPCA-1 (P ¼ .01) or gefitinib
plus AZD0530 (P < .001) (Figure 4). In order to examine the
hypothesis that there is a synergistic effect with the double and
triple combinations in the PC-9 sensitive to gefitinib xenograft
model, we used three different concentrations of gefitinib (2, 10,
50 mg/kg). Both the 10 mg/kg and 50 mg/kg dose groups showed
tumor regression with complete disappearance after 10 days of
treatment. Considering the high sensitivity of PC-9 cells to gefi-
tinib, we selected the low dose of 2 mg/kg of gefitinib to combine
with TPCA-1, AZD0530, or TPCA1 and AZD0530. This explains
the increase in the tumor volume observed in all groups until
the 15th day of treatment (Figure 4A). No substantial toxicity
was noted with the triple therapy approach. These in vivo re-
sults support a consistent synergistic effect of EGFR, STAT3, and
Src inhibition on EGFR-mutant NSCLC cells.
STAT3 and YAP1 as Biomarkers of Clinical Outcome to
EGFR Inhibition in EGFR-Mutant Patients
To test whether our findings were clinically relevant, we exam-
ined the mRNA levels of STAT3 and YAP1 in baseline samples of
64 EGFR-mutant NSCLC patients treated with firstline EGFR TKI
(Table 1). With a median follow-up of 26.7 months, median
progression-free survival was 9.6 months (95% CI¼ 5.9 to 14.1)
and 18.4 months (95% CI¼ 8.8 to 30.2) for patients with high and
low STAT3 mRNA, respectively (P < .001; HR for disease progres-
sion ¼ 3.02, 95% CI ¼ 1.54 to 5.93, P ¼ .001) (Figure 5A). Median
progression-free survival was 9.6 months (95% CI¼ 7.7 to 15.2)
and 23.4 months (95% CI¼ 13.0 to 28.1) for patients with high
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Figure 1. Effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with or without TPCA-1 (signal transducer and activator of transcription 3
[STAT3] inhibitor) on EGFR-regulated signal transduction pathways. A) Protein lysates from the PC-9 cell line treated with gefitinib (0.05lM) for 0 to 48 hours were col-
lected and assessed by immunoblot analysis. PC-9 cells were treated with different doses of gefitinib for 24 hours, and protein lysates were assessed by immunoblot
analysis. B) PC-9 cells were treated with gefitinib (0.05lM) in the absence or presence of increasing concentrations of TPCA-1 for 24 hours. Expression of different pro-
teins was analyzed using immunoblot analysis. C) STAT3 and Rantes mRNA expression were measured using quantitative reverse transcription polymerase chain re-
action in PC-9 cells that were treated with 0.05lM of gefitinib or 0.05lM of gefitinib plus 5 lM of TPCA-1 for nine days. Data were generated from a minimum of three
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and low YAP1 mRNA, respectively (P ¼ .005; HR for disease pro-
gression ¼ 2.57, 95% CI¼ 1.30 to 5.09, P ¼ .007) (Figure 5B).
Smoking status was also found to affect progression-free sur-
vival (Supplementary Table 2, available online). Using the for-
ward selection method, the STAT3 and YAP1 mRNA levels were
used for the Cox proportional hazards regression model. Only
STAT3 mRNA levels remained a statistically significant predic-
tor of progression-free survival (HR for disease progression ¼
2.99, 95% CI¼ 1.38 to 6.48, P ¼ .005) (Supplementary Table 3,
available online). Differences were observed in median overall
survival according to STAT3 and YAP1 mRNA expression
(Supplementary Figure 1, A and B, available online).
The time-dependent receiver operating characteristic (ROC)
curve analysis (20) revealed similar performance of STAT3 and
YAP1 in predicting progression-free survival (Supplementary
Figure 1C, available online). Given that we noted the cooperative
interplay between STAT3 and YAP1 signaling in limiting EGFR
TKI response in the preclinical studies and uncovered an inde-
pendent impact of STAT3 and YAP1 on clinical outcome (corre-
lation coefficient R ¼ 0.17, P ¼ .31), we reasoned that the
combined, rather than individual, biomarkers are better predic-
tors of outcome. Specifically, we divided 37 patients with evalu-
able STAT3 and YAP1 mRNA expression into three groups that
were defined according to the median expression of the two bio-
markers: one high-risk group with high STAT3 and high YAP1,
one low-risk group with low STAT3 and low YAP1, and one in-
termediate-risk group with either low STAT3 and high YAP1 or
low YAP1 and high STAT3. The median progression-free
survival in the low-risk, intermediate-risk, and high-risk was
25.7 months (95% CI¼ 8.5 to 60.9 months), 14.1 months (95%
CI¼ 8.2 to 23.4 months), and 9.4 months (95% CI¼ 2.8 to 15.2
months), respectively (P ¼ .004) (Figure 5C). Differences were ob-
served in overall survival according to the combined biomarkers
(Supplementary Figure 1D, available online).
The role of YAP1 and STAT3 was externally validated in 55
EGFR-mutant NSCLC patients treated with firstline EGFR TKI in
the Department of Oncology of Shanghai Pulmonary Hospital
(Table 1). With a median follow-up of 18.7 months, median
progression-free survival was 6.1 (95% CI¼ 4.0 to 9.8) and 13.2
months (95% CI¼ 8.7 to 17.4) for patients with high and low
STAT3 mRNA, respectively (P < .001; HR for disease progression
¼ 3.06, 95% CI¼ 1.66 to 5.64, P < .001) (Figure 5D). Median
progression-free survival was 6.1 months (95% CI¼ 5.1 to 8.2)
and 12.6 months (95% CI¼ 10.0 to 17.4) for patients with high
and low YAP1 mRNA, respectively (P ¼ .002; HR for disease pro-
gression ¼ 2.53, 95% CI¼ 1.37 to 4.66, P ¼ .003) (Figure 5E;
Supplementary Table 4, available online). The two-gene model
was also reconfirmed (Figure 5F). The type of EGFR mutation
was also found to predict progression-free survival in this co-
hort of patients. Median progression-free survival was 10.6
months (95% CI¼ 7.8 to 13.7) and 6.8 months (95% CI¼ 3.3 to
10.2) for patients with exon 19 deletion and L858R point muta-
tion, respectively (P < .001; HR for disease progression ¼ 0.52,
95% CI¼ 0.29 to 0.93, P ¼ .03). Using the forward selection
method, the STAT3 mRNA levels and the type of EGFR mutation
were used for the Cox proportional hazards regression model.
Both parameters remained statistically significant predictors of
progression-free survival (Supplementary Table 5, available on-
line). Median survival time was not reached for this cohort of
patients. After 54 months of follow-up, 60.3% of patients (95%
CI¼ 38.54 to 76.52) were alive. These data identify STAT3 and
YAP1 levels, alone and combined, as a novel predictive bio-
marker of initial EGFR TKI response in lung cancer patients.
Our results showed differences in progression-free survival
between patients with high and low STAT3 mRNA expression,
according to the type of the EGFR mutation (P ¼ .002)
(Supplementary Table 6, available online). Among patients with
the exon 19 deletion, STAT3 levels statistically significantly af-
fected progression-free survival (P ¼ .004). Statistically signifi-
cant differences in progression-free survival were also observed
between patients with high and low YAP1 mRNA expression,
according to the type of the EGFR mutation (P ¼ .02). Among pa-
tients with exon 19 deletion, YAP1 levels statistically signifi-
cantly affected progression-free survival (P ¼ .007). No
statistically significant differences were noted in progression-
free survival among patients with the L858R mutation at exon
21 according to STAT3 or YAP1 mRNA expression levels. Similar
results were obtained in the validation cohort (Supplementary
Table 6 and Supplementary Figure 2, available online).
Discussion
Our study reveals that dual STAT3 and Src-YAP1 activation lim-
its EGFR TKI efficacy in EGFR-mutant NSCLC. STAT3 and YAP1
mRNA levels, as well as the STAT3-YAP1 composite score, were
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Figure 2. Effect of epidermal growth factor receptor (EGFR) and signal transducer
and activator of transcription 3 (STAT3) inhibition on the YES-associated protein
1 (YAP1) signaling pathway. connective tissue growth factor mRNA expression
was measured using quantitative reverse transcription-polymerase chain reac-
tion in PC-9 cells that were treated with 0.05lM of gefitinib or 0.05lM of gefitinib
plus 5 lM of TPCA-1 for nine days. Data were generated from a minimum of
three replicates. b-actin was used to normalize gene expression. Data are pre-
sented as the means 6 standard deviation; *P ¼ .04, **P ¼ .002 (two-sided
Student’s t test). CTGF ¼ connective tissue growth factor.
Figure 1. Continued
replicates. b-actin was used to normalize gene expression. Data are presented as the means 6 standard deviation; *P ¼ .04, **P ¼ .01 (two-sided Student’s t test). D)
Extracts from the 11-18 cell line were treated with 0.8 lM gefitinib, TPCA-1 (5 lM), or gefitinib combined with TPCA-1 for 24 hours. E) H1975 cells were treated with
AZD9291 (0.05 lM) in the absence or presence of TPCA-1 (5 lM) for 24 hours. Expression of different proteins was analyzed by immunoblot analysis. BIM ¼ Bcl2 interact-
ing mediator of cell death; EGFR ¼ epidermal growth factor receptor; STAT3 ¼ signal transducer and activator of transcription 3.
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Figure 3. Effects of the triple combination of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), TPCA-1, and AZD0530 in PC-9 and H1975 cells.
Extracts from (A) the PC-9 cell line treated with gefitinib (0.05lM), TPCA-1 (5 lM), or AZD0530 (0.5 lM), or double and triple combinations for 24 hours and (B) the H1975
cell line treated with AZD9291 (0.05 lM), TPCA-1 (5 lM), or AZD0530 (0.5 lM), or double and triple combinations for 24 hours, were analyzed for indicated antibodies as
well as b-actin as a loading control to confirm equal gel loading by immunoblot analysis. Similar results were obtained in three independent experiments. C) PC-9 cells
were treated with serial dilutions of gefitinib, TPCA-1, AZD0530 alone and with their double and triple combinations for 72 hours. The cell viability was measured by
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Figure 3. Continued
MTT, and the synergy between the drugs was determined using the Chou and Talalay method (Chou and Talalay plot or Fa plot). The dotted horizontal line at 1 indi-
cates the line of additive effect. Effect (Fa) indicates the fractional inhibition for each combination index. To calculate drug concentration for each Fa point, the drugs
were mixed using constant ratios corresponding to 1/8, 1/4, 1/2, 5/8, 3/4, 7/8, 1, 1.5, and 2 of the individual IC50 values for each drug in the PC-9 cell line. The results rep-
resent the means of at least three independent experiments. Data are presented as the means 6 standard deviation. D) H1975 cells were treated with serial dilutions of
AZD9291, TPCA-1, AZD0530 as a triple combination for 72 hours, a procedure similar to those described in (C). E) PC-9 cells grown in six-well plates (1000 cells/well) for
24 hours and then left untreated or treated with gefitinib, TPCA-1, and AZD0530 alone and with their double and triple combinations. After 72 hours, media was
replaced with fresh media without drugs. After seven more days, cells were washed and stained with crystal violet and then photographed. The crystal violet was ex-
tracted and assayed by spectrophotometry. The absorbance was measured at 570 nm. Gefitinib was used at 0.05lM, TPCA-1 at 5 lM, and AZD0530 at 0.5 lM. Data are
means 6 standard deviation of three independent experiments. *P ¼ .04, gefitinib plus TPCA-1 vs control; †P ¼ .003, gefitinib plus AZD0530 vs control; ‡P ¼ .03, gefitinib
plus TPCA-1 plus AZD0530 vs gefitinib plus TPCA-1; §P ¼ .05, gefitinib plus TPCA-1 plus AZD0530 vs gefitinib plus AZD0530 (two-sided Student’s t test). BIM ¼ Bcl2 inter-
acting mediator of cell death; EGFR ¼ epidermal growth factor receptor; STAT3 ¼ signal transducer and activator of transcription 3; YAP1 ¼ YES-associated protein 1.
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Figure 4. Effect of epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), and Src co-inhibition in vivo. A) Mice with estab-
lished PC-9 tumors were treated with vehicle control, gefitinib alone, TPCA-1 alone, AZD0530 alone, gefitinib and TPCA-1, gefitinib and AZD0530 or gefitinib, TPCA-1,
and AZD0530. Each point represents the mean 6 standard deviation of the tumor volume (n¼4 per group). Initially, different concentrations of gefitinib (2, 10, 50 mg/
kg) were used. Both the 10 mg/kg and 50 mg/kg dose groups showed tumor regression with complete disappearance after 10 days of treatment. Considering the high
sensitivity of PC-9 cells to gefitinib, a very low concentration of gefitinib (2 mg/kg) was finally used in this experiment, which explains the shape of the survival curves.
Statistically significant differences on day 30 are shown for gefitinib plus AZD0530 vs gefitinib alone (*P < .001), gefitinib plus TPCA-1 vs gefitinib alone (†P < .001), and
the triple combination of gefitinib, TPCA-1, and AZD0530 vs gefitinib plus AZD0530 (‡P < .001) and vs gefitinib plus TPCA-1 (§P ¼ .01). B) After 30 days, the mice were
killed and the tumors removed and weighed. Tumor weights were individually plotted, and comparisons between control and treatment groups were analyzed by
Student’s t test. Representative tumor pictures were taken. The reduction in tumor weight obtained with gefitinib plus TPCA-1 or gefitinib plus AZD0530 in the PC-9 xe-
nograft model was statistically significantly different compared with gefitinib alone (†P < .001 and *P ¼ .009, respectively). The reduction in tumor weight obtained with
the triple combination of gefitinib, TPCA-1, and AZD0530 was statistically significantly different compared with gefitinib plus TPCA-1 (§P ¼ .03) and gefitinib plus
AZD0530 (‡P < .001). C) Representative tumors surgically removed. The two-sided Student’s t test was used for the statistical analysis. EGFR ¼ epidermal growth factor
receptor; STAT3 ¼ signal transducer and activator of transcription 3; YAP1 ¼ YES-associated protein 1.
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highly predictive of progression-free survival in the original as
well as in the validation cohort of EGFR-mutant NSCLC patients,
a clinical biomarker discovery that warrants future prospective
clinical validation.
We have shown that EGFR inhibition results in the adaptive
activation of not only STAT3 but also Src-YAP1 signaling, po-
tentially operating downstream of IL-6, to promote cell sur-
vival and limit the initial response to EGFR TKI treatment in
EGFR-mutant lung cancer (Figure 6). Our data offer the first evi-
dence, to our knowledge, that Src-YAP1 signaling limits EGFR
TKI response, in conjunction with STAT3, in lung cancer. EGFR
mutations activate MAPK, PI3K-AKT, and STAT3 directly or
through IL-6-JAK2 (5,10,21). An IL-6-mediated crosstalk be-
tween NF-jB and STAT3 has been described in EGFR-mutant
NSCLC cells (16). pSTAT3-Tyr705 is induced two hours after
erlotinib or gefitinib treatment (7,8,16). Further, pSTAT3-
Tyr705 is abrogated by a pan-JAK inhibitor (Pyridone 6) (21) or
TPCA-1 (16) but not by EGFR TKIs or Src inhibitors (21). In our
study, similar to gefitinib, the FDA-approved third-generation
EGFR TKI AZD9291 (osimertinib) also failed to suppress STAT3
activation in EGFR-mutant cells. Our study sheds new light on
the context in which STAT3 activation can limit EGFR TKI re-
sponse, revealing a previously unappreciated interplay with
other pathways, including Src-YAP1 signaling, that coopera-
tively buffer cells from the effects of EGFR TKI treatment
(Figure 6).
We previously showed that YAP1 causes RAF and MEK inhib-
itor resistance in BRAF- and RAS-mutant tumors and predicts
poor clinical response to RAF and MEK inhibition, but we did
not previously examine the role of YAP1 in modulating EGFR
TKI response in EGFR-mutant NSCLC (14). While conducting our
study, it was reported that gp130 (a coreceptor for IL-6) can acti-
vate YAP1 independently of STAT3 through direct association
with SFKs in colorectal cancer cells (12). An earlier report shows
that cotargeting STAT3 and Src or STAT3 and EGFR induced
pancreatic tumor cell growth inhibition (22). We evaluated
STAT3 and Src-YAP1 signaling activity in PC-9 and H1975 cells
and showed that Src-induced phosphorylation of paxillin and
YAP1 at tyrosines 118 and 357, respectively (23), was inhibited
with gefitinib plus AZD0530. The triple combination of gefitinib,
TPCA-1, and AZD0530 fully abrogated STAT3, paxillin, and YAP1
phosphorylation. Tumors in nude mice showed near-complete
suppression by the triple combination without signs of substan-
tial toxicity, suggesting both efficacy and a wide therapeutic
window for potential clinical feasibility of this polytherapy
strategy.
Our study has a few limitations, such as the use of a rather
small panel of in vitro and in vivo models to demonstrate the ef-
ficacy of cotargeting EGFR, STAT3, and Src-YAP1. Nevertheless,
our preclinical findings accurately model EGFR-mutant NSCLC
and uncover a previously unappreciated role of the coordinated
activation of both STAT3 and Src-YAP1 signaling as a
Figure 6. Epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), and Src-YES-associated protein 1 (YAP1) crosstalk. EGFR-
activating mutations located in the tyrosine kinase domains and mainly in the form of a base-pair deletion at exon 19 (DE746_A750) or a point mutation at exon 21
(L858R) enhance cell growth and invasion via tyrosine phosphorylation and lead to the activation of mitogen-activated protein kinase (MAPK), STAT3, and AKT path-
ways. Ras-ERK signaling promotes cell growth and decreases apoptosis-related BIM expression. SHP2 modulates signals of receptor tyrosine kinases at the level of Ras.
Phosphorylation of the tyrosine residue 705 of cytoplasmic STAT3 in response to activated EGFR promotes STAT3 homodimerization, which leads to nucleus transloca-
tion and DNA binding. IL-6 signals via receptor complexes, which contain gp130, the common signal-transducing protein of the IL-6 family of cytokines and IL-6R. IL-
6R is not a signal transducer, but its function is to present IL-6 to the signal-transducer gp130, resulting in phosphorylation of gp130 by JAK2 and recruitment of STAT3.
In EGFR TKI–resistant cells, paracrine or autocrine stimulation of the TGF-b axis drives expression of IL-6 and activation of STAT3, unleashing the cells from their EGFR
activity dependency. gp130 associates with Src and YES and triggers activation of YAP1 through phosphorylation on the tyrosine residue 357, independently of STAT3.
YAP1 is normally kept inactive in the cytoplasm through phosphorylation on serine residue 127 by the Hippo effector kinase LATS. EGFR inhibition promotes immedi-
ate ubiquitination of TRAF2, which is essential for RIP1 and IKK activation, IkB phosphorylation, and degradation and NF-jB (RelA) nuclear translocation. NF-jB-in-
duced IL-6 ensures STAT3 activation. TPCA-1 is a STAT3 inhibitor. AZD0530 (saracatinib) is a potent, orally administered small molecule that inhibits Src by blocking
the ATP-binding site of Src kinases. BIM ¼ Bcl2 interacting mediator of cell death; CTGF ¼ connective tissue growth factor; ERK ¼ extracellular signal-regulated kinase;
gp130 ¼ glycoprotein 130; IkB ¼ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor; IKK ¼ IkB kinase; IL-6 ¼ interleukin 6; IL-6R ¼ IL-6 receptor;
JAK2 ¼ Janus kinase 2; LATS1/2 ¼ large tumor suppressor kinase 1 and 2; MEK ¼ mitogen-activated protein kinase; MTOR ¼ mechanistic target of rapamycin; P 70 S6K
¼ ribosomal protein S6 kinase beta-1; NF-jB ¼ nuclear factor kappa light chain enhancer of activated B cells; PI3K ¼ phosphatidylinositide 3 kinase; P XN ¼ paxillin;
RelA ¼ v-rel reticuloendotheliosis viral oncogene homolog A; RIP1 ¼ receptor-interacting protein 1; Ser ¼ serine; SHP2 ¼ Src homology region 2–containing protein tyro-
sine phosphatase 2; STAT3 ¼ signal transducer and activator of transcription 3; TEAD1 ¼ TEA domain transcription factor 1; TGF-beta ¼ transforming growth factor
beta; Thr ¼ threonine; TRAF2 ¼ TNF receptor–associated factor 2; Tyr ¼ tyrosine; YAP1 ¼ YES-associated protein 1.
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compensatory response to EGFR TKI therapy. Although the as-
sessment of STAT3 and YAP mRNA in EGFR-mutant NSCLC pa-
tients treated with EGFR TKI was retrospective, the predictive
role of STAT3 and YAP mRNA was validated in an independent
cohort of patients. Based on our findings, we are currently in-
vestigating the cotargeting of EGFR, STAT3, and Src-YAP1 with
the aim of establishing a phase I clinical trial.
In conclusion, EGFR TKI monotherapy is inadequate for pa-
tients with EGFR-mutant NSCLC. Our data provide evidence that
co-activation of a broader network of signaling events than pre-
viously appreciated limits the initial cellular response to EGFR
TKI treatment by providing prosurvival signals that facilitate
the survival of residual disease cells. Critically, our findings sug-
gest that biomarker-driven clinical trials cotargeting STAT3,
Src-YAP1, and mutant EGFR with existing agents are warranted
to improve the initial efficacy of EGFR TKI treatment, minimize
residual disease, and potentially prevent the emergence of re-
sistance to enhance patient survival.
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